ENDURANCE trial finds fixed 2-year lenalidomide maintenance matches continuous therapy for standard-risk multiple myeloma survival, guiding oncology pharmacists on MM regimen toxicity.
|Podcasts|April 17, 2023
Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma
Advertisement
Pharmacists play a key role in treatment sequencing and educating patients, according to Tyler Sandahl, PharmD, a clinical pharmacist with Mayo Clinic. In addition to discussing the role of CAR T-cell therapies, Sandahl said pharmacists are crucial team members in addressing adverse effects and ensuring patients have optimal outcomes and quality of life.
Interested in learning more? Check out this related content:
Advertisement
Related to this article
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
A retrospective study of pharmacist-supported mirogabalin treatment highlights the need for careful evidence interpretation and sustained follow-up in cancer-related neuropathic pain.
The approval gives patients aged 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.
Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Combined Cardiometabolic Biomarker Burden Tracks CKM Progression
2
Flu Vaccination Linked to Fewer Severe Outcomes in Older Adults, Fewer ED Visits in Children
3
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
4
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
5